Parkinson’s disease: new real-world data available on safinamide
28th April 2021
ADVERTISEMENT FEATURE
Dr Jason Raw outlines key findings from the SYNPASES trial, which explored the tolerability of safinamide used as an adjunct therapy in patients with Parkinson s disease
Zambon has officially presented the results from SYNAPSES, its multinational, multicentre, retrospective/prospective cohort observational study that explored the tolerability of safinamide used as an adjunct therapy in 1,610 patients followed up to 12 months. The study was designed to include potentially all patients treated with safinamide as per clinical practice
1, and investigate the real-world use of safinamide in six European countries including the UK, particularly in patient populations not well represented in clinical trials such as those older than 75, those with psychiatric illnesses or those with relevant comorbidities.